Annals of Cancer Research and Therapy
Online ISSN : 1880-5469
Print ISSN : 1344-6835
Original Articles
Titration of serum CEA, p53 antibodies and CEA-IgM complexes in 142 patients with colorectal cancer and 150 healthy blood donors.
Taiki KojimaTakanori MatsuiYasunobu FujimitsuHiroshi KojimaHayato UnoKazuhiro HiramatsuHitoshi InagakiKazushige OdaAkiharu IshiyamaNaoki IwataGoro NakayamaYasuhiro Kodera
Author information

2011 Volume 19 Issue 1 Pages 15-19


Background: The early detection of colorectal cancer is important issue for improving the survival rate. Although fecal occult-blood testing and Carcinoembryonic antigen (CEA) in serum is widely used for noninvasive screen method, it has limited sensitivity.
Methods: 142 patients with primary colorectal cancer who underwent surgery and 150 healthy volunteers were enrolled in this study. 37 of the tumors (26%) were Stage I, 34 (24%) were Stage II, 58 (41%) were Stage III, 12 (9%) were Stage IV. In each serum sample, CEA, p53 antibodies, and CEA-IgM complexes were measured.
Results: The diagnostic sensitivity with CEA (cut-off: 5 ng/ml) and p53 antibodies (cut-off: 3.0 U/ml) was 48% (68/142), Stage I 16% (6/37), Stage II 56% (19/34), Stage III 53% (31/58), and Stage IV 92% (12/13), while false positive rate was 7% (10/150). Because the sensitivity of CEA-IgM (cut-off: 150 AU/ml) was low, three tests combination did not much increase the overall sensitivity.
Conclusions: The sensitivity of CEA-IgM for detecting colon cancer was lower than expected from previous study. As for the specificity of p53-antibodies, because its sensitivity is preserved with cut-off at 3.0 U/ml, re-evaluation of present cut-off level (1.3 U/ml) seemed to be needed.

Information related to the author
© 2011 by The Japanese Society of Strategies for Cancer Research and Therapy
Previous article Next article